Last reviewed · How we verify
NCT04784624
Virtual Lifestyle Program Evaluation During Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
trial testing Lifestyle program in Cardiometabolic Syndrome in 100 participants. Status unknown.
31 May 2022
Quick facts
| Lead sponsor | University of Manitoba |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 March 2021 |
| Primary completion | 31 May 2022 |
| Estimated completion | 31 July 2022 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Lifestyle program
Conditions studied
- Cardiometabolic Syndrome — all drugs for Cardiometabolic Syndrome →
- Weight Loss — all drugs for Weight Loss →
Sponsor
University of Manitoba
Who can join
18 and older, any sex, with Cardiometabolic Syndrome or Weight Loss. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a pilot study evaluating an online cardiometabolic and weight loss program which is offered by The Wellness Institute. The program is 16 weeks and is developed by a multidisciplinary team and delivered by a degreed health professional (health coach) to assist participants in achieving their personal wellness goals. This study will also investigate the impact of Coronavirus Disease (COVID-19) on participants lifestyles and access to lifestyle programs and supports.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04784624
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lifestyle program
Trials testing the same drug.
- NCT07427433 — Amygdala Insula Retraining in the Management of Multiple Sclerosis Symptoms · NA · completed
- NCT05870878 — Generation R Next - Optimaal Opgroeien · NA · recruiting
- NCT05084274 — Optimising Preconceptual Health in Subfertile PCOS Patients Using a Lifestyle Modification Program · NA · terminated
Other recruiting trials for Cardiometabolic Syndrome
Currently open trials in the same condition.
- NCT06865885 — LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering · Phase 4 · recruiting
- NCT06645691 — Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body · Phase 2 · recruiting
- NCT06784154 — The Role of Ectopic Fat and Heart Attack Risk in HIV · recruiting
- NCT06277661 — The Mom and Infant Outcomes (MOMI) Study · NA · recruiting
- NCT06538714 — Interval Training and Cardio-metabolic Health in Overweight/Obese Girls · NA · recruiting
Other University of Manitoba trials
Trials by the same sponsor.
- NCT07528417 — Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) · Phase 2 · not yet recruiting
- NCT07366515 — Feasibility of a Multimodal Virtual Reality Intervention to Reduce Preoperative Anxiety in Cancer Surgery Patients · NA · not yet recruiting
- NCT07354386 — Effects of Dried Whole Fruits on Metabolism in Diabetes · NA · enrolling by invitation
- NCT07361315 — Development and Online Evaluation of an Online Course for Parasomnias · NA · recruiting
- NCT07023744 — CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04784624 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Manitoba
- Last refreshed: 29 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04784624.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing